M. Lindon

发表

The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.

Carsten Hopf, Chun-Wa Chung, Marcus Bantscheff, 2014, ACS chemical biology.

Application of Atypical Acetyl-Lysine Methyl Mimetics in the Development of Selective Inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains.

Melanie V. Leveridge, P. Grandi, A. Michon, 2020, Journal of medicinal chemistry.

Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11

R. Prinjha, D. Tough, I. Rioja, 2014, British journal of pharmacology.

Palladium catalyzed tandem alkenyl- and aryl-C-N bond formation: a cascade N-annulation route to 4-, 5-, 6- and 7-chloroindoles

M. Willis, L. Henderson, M. Lindon, 2010 .

Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation

P. Grandi, A. Michon, G. Drewes, 2020, Science.

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.

Andrew J. Bannister, Melanie V. Leveridge, S. Robson, 2016, Journal of medicinal chemistry.

Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B

Stefan Knapp, Susanne Müller, Chun-Wa Chung, 2015, Journal of medicinal chemistry.

The Optimisation of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.

P. Grandi, A. Michon, I. Wall, 2020, Journal of medicinal chemistry.

Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.

P. Bamborough, R. Prinjha, C. Chung, 2018, Journal of medicinal chemistry.

A novel series of potent γ-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core

J. Best, J. G. Neduvelil, J. Castro, 2005 .

Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'.

P. Thomas, Jonathan D Goodacre, Lena Shukla, 2020, Bioorganic & medicinal chemistry letters.

BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells.

H. Mei, R. Prinjha, Zhong Zhong, 2016, Stem cell research.

Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe.

P. Grandi, A. Michon, P. Bamborough, 2017, Journal of medicinal chemistry.

Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment Screening.

Darren L. Poole, Tony W Dean, I. Wall, 2020, Journal of medicinal chemistry.

A novel series of potent gamma-secretase inhibitors based on a benzobicyclo[4.2.1]nonane core.

J. Best, J. G. Neduvelil, J. Castro, 2005, Bioorganic & medicinal chemistry letters.

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.

James M. Woolven, P. Bamborough, R. Prinjha, 2020, Journal of medicinal chemistry.

The Design and Synthesis of a Highly Selective and In Vivo Capable Inhibitor of the Second Bromodomain (BD2) of the Bromodomain and Extra Terminal Domain (BET) Family of Proteins.

P. Grandi, A. Michon, I. Wall, 2020, Journal of medicinal chemistry.

Oxazolidinones as novel human CCR8 antagonists.

Dwight M. Morrow, H. Sarau, J. Foley, 2007, Bioorganic & medicinal chemistry letters.

Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor.

J. D. Elliott, Wei Zhang, Yonghui Wang, 2012, Bioorganic & medicinal chemistry letters.

Discovery of thiadiazole amides as potent, S1P₃-sparing agonists of sphingosine-1-phosphate 1 (S1P₁) receptor.

J. D. Elliott, Wei Zhang, Yonghui Wang, 2012, Bioorganic & medicinal chemistry letters.

The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains.

P. Grandi, G. Drewes, G. Neubauer, 2014, ACS chemical biology.

INTERNATIONAL UNION OF BASIC AND CLINICAL PHARMACOLOGY REVIEW Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11

R. Prinjha, D. Tough, I. Rioja, 2014 .